Athenex Ruling Helps Clarify FDA Drug Compounding Policy

August 9, 2019Law360

Reading Time : 1 min

Health Care & Life Sciences partner Nate Brown authors article with Law30 on Athenex ruling and its impact on clarifying the FDA drug compounding policy.

Excerpt from Law360:

On Aug. 1, 2019, the U.S. District Court for the District of Columbia affirmed the U.S. Food and Drug Administration's decision to exclude the bulk drug substance vasopressin from the agency's List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act, or 503B bulks list, in Athenex Pharma Solutions LLC v. Azar II.

For the full article, click here.

Share This Insight

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.